PANCAID (PANcreatic CAncer Initial Detection via liquid biopsy) is an ambitious international research consortium that aims to make significant advancements in the early detection of pancreatic cancer through the development of a minimally invasive blood test. The project utilizes a comprehensive panel of liquid biopsy diagnostics, which involves analyzing genetic mutations, circulating tumor cells, and other biomarkers in blood samples, to detect pancreatic cancer at an early stage. This innovative approach has the potential to revolutionize the current methods of pancreatic cancer diagnosis, which often occur at later stages of the disease.
The PANCAID project is a multi-site, interdisciplinary research consortium that involves 17 partners + 1 associated partner from eight countries, bringing together expertise from various fields such as oncology, molecular biology, bioinformatics, and clinical research. This collaborative effort allows for a diverse range of perspectives and expertise, which may contribute to breakthrough scientific discoveries and novel insights into the biology of pancreatic cancer development.
PANCAID is committed to fostering gender balance in decision making, ensuring gender balance in research teams, and integrating the gender dimension in research and innovation.
The project has received funding for a duration of five years, which allows for in-depth investigations, robust data collection, and comprehensive analysis, which may lead to significant advancements in the field of pancreatic cancer detection.
The commencement of the PANCAID project in January 2023 marks the beginning of a new chapter in the fight against pancreatic cancer. Through international collaboration, cutting-edge liquid biopsy diagnostics, and a dedicated research effort spanning multiple years, PANCAID aims to make a meaningful impact in the early detection and improved treatment of pancreatic cancer, with the ultimate goal of saving lives and improving patient outcomes.